We explore the evidence that informs ambulatory care pharmacy practice. Check out our website & podcasts, & consider submitting a commentary!
Episodes
Friday Jul 10, 2015
Friday Jul 10, 2015
The American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guidelines acknowledge that “CSII is a less commonly used and more costly alternative” to basal-bolus therapy in patients with T2DM. The Opt2mise was a robust study intended to clarify the role of CSII in patients with T2DM.
No comments yet. Be the first to say something!